CUE vs. QTTB, NBTX, AVIR, KMDA, XOMA, ADCT, CRMD, MRSN, VNDA, and NATR
Should you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include Q32 Bio (QTTB), Nanobiotix (NBTX), Atea Pharmaceuticals (AVIR), Kamada (KMDA), XOMA (XOMA), ADC Therapeutics (ADCT), CorMedix (CRMD), Mersana Therapeutics (MRSN), Vanda Pharmaceuticals (VNDA), and Nature's Sunshine Products (NATR). These companies are all part of the "pharmaceutical preparations" industry.
Q32 Bio (NASDAQ:QTTB) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.
Q32 Bio has a net margin of 0.00% compared to Q32 Bio's net margin of -711.84%. Cue Biopharma's return on equity of -117.63% beat Q32 Bio's return on equity.
Q32 Bio has a beta of -0.26, meaning that its stock price is 126% less volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500.
Q32 Bio presently has a consensus price target of $49.67, suggesting a potential upside of 89.57%. Cue Biopharma has a consensus price target of $8.00, suggesting a potential upside of 403.14%. Given Q32 Bio's higher probable upside, analysts clearly believe Cue Biopharma is more favorable than Q32 Bio.
Cue Biopharma received 139 more outperform votes than Q32 Bio when rated by MarketBeat users. However, 100.00% of users gave Q32 Bio an outperform vote while only 51.81% of users gave Cue Biopharma an outperform vote.
31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 16.1% of Q32 Bio shares are held by insiders. Comparatively, 7.5% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Cue Biopharma has higher revenue and earnings than Q32 Bio. Cue Biopharma is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cue Biopharma had 1 more articles in the media than Q32 Bio. MarketBeat recorded 4 mentions for Cue Biopharma and 3 mentions for Q32 Bio. Cue Biopharma's average media sentiment score of 1.68 beat Q32 Bio's score of 1.43 indicating that Q32 Bio is being referred to more favorably in the media.
Summary
Cue Biopharma beats Q32 Bio on 10 of the 19 factors compared between the two stocks.
Get Cue Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cue Biopharma Competitors List
Related Companies and Tools
